2024
Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review
Shitara K, Falcone A, Fakih M, George B, Sundar R, Ranjan S, Van Cutsem E. Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review. The Oncologist 2024, 29: e601-e615. PMID: 38366864, PMCID: PMC11067808, DOI: 10.1093/oncolo/oyae007.Peer-Reviewed Original ResearchConceptsMetastatic colorectal cancerRefractory metastatic colorectal cancerAdverse eventsDiscontinuation rate due to adverse eventsColorectal cancerChemorefractory metastatic colorectal cancerSafety outcomesMedian overall survivalSafety of FTD/TPIProgression-free survivalAdvanced solid tumorsAssociated with improved outcomesEarly-phase studiesSystematic reviewOverall survivalFTD/TPIRetrospective studySolid tumorsBevacizumabClinical efficacyTargeted agentsTumor typesAntineoplastic agentsAdvanced cancerImprove outcomesUnveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burden
Provenzano L, Gwee Y, Conca V, Lonardi S, Bozzarelli S, Tamburini E, Passardi A, Zaniboni A, Tosi F, Aprile G, Nasca V, Boccaccino A, Ambrosini M, Vetere G, Carullo M, Guaglio M, Battaglia L, Zhao J, Chia D, Yong W, Tan P, So J, Kim G, Shabbir A, Ong C, Casella F, Cremolini C, Bencivenga M, Sundar R, Pietrantonio F. Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burden. Therapeutic Advances In Medical Oncology 2024, 16: 17588359241289517. PMID: 39502404, PMCID: PMC11536604, DOI: 10.1177/17588359241289517.Peer-Reviewed Original ResearchMetastatic colorectal cancerMetastatic gastric cancerMetastatic gastric cancer patientsPeritoneal metastasisMalignant ascitesAdvanced gastrointestinal cancerSurvival outcomesMedian peritoneal cancer index scoreGastrointestinal cancerPeritoneal cancer index scoreGastric cancerMetastatic colorectal cancer patientsSubgroup of patientsMedian OSProgression-freeOverall survivalSystemic therapyPrognostic significancePatient survivalAscites groupPoor outcomeRetrospective analysisColorectal cancerRandomized trialsAscites
2023
593P Role of circulating tumor DNA (ctDNA) in assessing primary anti–epidermal growth factor receptor (EGFR) resistance in untreated RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) patients (pts)
Loh J, Choo J, Sooi K, Low P, Ang C, Sundar R, Walsh R, Wijaya S, Low J, Hsing S, Jain S, Chee C. 593P Role of circulating tumor DNA (ctDNA) in assessing primary anti–epidermal growth factor receptor (EGFR) resistance in untreated RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) patients (pts). Annals Of Oncology 2023, 34: s429. DOI: 10.1016/j.annonc.2023.09.1784.Peer-Reviewed Original Research
2022
Real-world experience on the efficacy and tolerability of biweekly trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer.
Ang C, Low Q, Ho C, Walsh R, Asokumaran Y, Choo J, Chan G, Ho J, Ang Y, Tan L, Yong W, Sundar R, Chee C. Real-world experience on the efficacy and tolerability of biweekly trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer. Journal Of Clinical Oncology 2022, 40: 3584-3584. DOI: 10.1200/jco.2022.40.16_suppl.3584.Peer-Reviewed Original ResearchMetastatic colorectal cancerTAS-102Median PFSBiweekly dosesDiscontinued treatment due to toxicityColorectal cancerDose of TAS-102Treated with TAS-102Treatment due to toxicityMetastatic colorectal cancer patientsGrade 3 neutropeniaThird-line treatmentInitiation of treatmentRetrospective observational studyBiweekly regimenDose delaysFebrile neutropeniaHigher neutropeniaStandard regimenDose reductionBevacizumabGrade 3Adverse eventsDisease progressionNeutropenia